Acikel, C.

Akar, S.

Berdeli, A.

Demirkaya, E.

Direskeneli, H.

Erten, S.

Fidanci, B. E.

Gok, F.

Goker, B.

Gul, A.

Kasifoglu, T.

Kisacik, B.

Onat, A. M.

Ozcelik, G.

Ozden, A.

Ozen, S.

Sayarlioglu, M.

Senel, S.

Simsek, D.

Tufan, A.

Tunca, M.

Yavuz, S.

Yesilkaya, S.

Yildiz, F.

Pediatric Rheumatology

English

PubMed

BE Fidanci

S Yesilkaya

C Acikel

A Ozden

D Simsek

F Yildiz

B Kisacik

M Sayarlioglu

S Akar

S Senel

M Tunca

S Yavuz

A Tufan

A Berdeli

AM Onat

A Gul

B Goker

T Kasifoglu

H Direskeneli

S Erten

G Ozcelik

F Gok

S Ozen

E Demirkaya

Springer - Publisher Connector

Validity and reliability of medication adherence scale in FMF

POSTER PRESENTATION Open Access
Validity and reliability of medication adherence
scale in FMF
BE Fidanci, S Yesilkaya, C Acikel, A Ozden, D Simsek*, F Yildiz, B Kisacik, M Sayarlioglu, S Akar, S Senel, M Tunca,
S Yavuz, A Tufan, A Berdeli, AM Onat, A Gul, B Goker, T Kasifoglu, H Direskeneli, S Erten, G Ozcelik, F Gok, S Ozen,
E Demirkaya
From 8th International Congress of Familial Mediterranean Fever and Systemic Autoinflammatory Diseases
Dresden, Germany. 30 September - 3 October 2015
Objective
The optimal level of adherence necessary to achieve
acceptable disease and quality-of-life outcomes for
patients is not known. In order to identify these optimal
levels, we need reliable and valid measures of adherence.
Medication Adherence Scale in FMF (MASIF) is an
instrument designed to measure adherence to treatment
in children with Familial Mediterranean Fever (FMF).
We have developed this scale for children with FMF
and found valid and reliable. In this study, it was aimed
to assess the validity and reliability of this adherence
scale for medical treatment in adult FMF patients.
Methods
This study is multicentre and 14 centers participated to
the study. Patients with FMF using medication at least
for 6 months and accepted to participate constituted the
sample of the study. Besides “Medication Adherence
Scale in FMF Patients (MASIF)”, “Data collection forms
about the sociodemographic and medical information
(demographic, clinical and laboratory findings) of
patients”, and “Morisky Medication Adherence Scale
(MMAS)” were used as data collection instruments.
Morisky medication adherence scale was used as a gold
standard in order to evaluate the criterion validity of
MASIF. We assessed the validity of the adult version of
the MASIF using the Outcome Measures in Rheumatoid
Arthritis Clinical Trials (OMERACT) filter.
Results
There were 133 patients with FMF enrolled for the vali-
dation of the study. The median age of the patients
(n=133) was 28.60 years (min.18.12-max.71.34) and
52.6% of them were female. The median number of the
attack frequency was 13.50 (min. 0-max 99) in a year
and 57.9% of the participants had irregular attacks. For
internal consistency, Cronbach’s alpha was 0,764 for
MASIF adult version. Also, there was a positive and sig-
nificant correlation between test and retest score
(t=0.971; p=0.340). For the “criterion validity” the corre-
lation with Morisky and MASIF was evaluated (r=0.530,
p=0.000) and for the “structure” validity, factor analyzes
and Kaiser-Meyer-Olkin tests were performed. After
these tests, MASIF was found as a valid and reliable
instrument. MASIF consists of 18 items and 4 sub-
dimensions: knowledge about the medication, adherence
to the treatment, barriers to drug use, factors that may
increase compliance. The participants answered each
item on a Likert scale (1=strongly agree, 2=agree, 3=no
idea, 4=disagree, 5=strongly disagree). The total score
ranged from 18 to 90. A high score showed a good
adherence to treatment. The cut-off point was deter-
mined as 55 points. A point over 55 was accepted as
“good medication adherence” and a point less than 55
was considered as “bad medication adherence”
Conclusion
Approximately 10-15% of patients with FMF are non-
responders but it was claimed that in fact they are non-
compliers that causes these patients receive unnecessary
biologic agent treatment procedures, which are expen-
sive and have some serious adverse effects. This scale
will provide assessment and follow up of adherence to
treatment patients and determine whether the patient is
non-responders or non-compliers. It may help to deter-
mine the non-compliance and prevent unnecessary and
expensive biologic agents.FMF Arthritis Vasculitis and Orphan Disease Research in PaediatricRheumatology (FAVOR), Ankara, Turkey
Fidanci et al. Pediatric Rheumatology 2015, 13(Suppl 1):P112
http://www.ped-rheum.com/content/13/S1/P112
© 2015 Fidanci et al. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://
creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the
original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/
zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Published: 28 September 2015
doi:10.1186/1546-0096-13-S1-P112
Cite this article as: Fidanci et al.: Validity and reliability of medication
adherence scale in FMF. Pediatric Rheumatology 2015 13(Suppl 1):P112.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Fidanci et al. Pediatric Rheumatology 2015, 13(Suppl 1):P112
http://www.ped-rheum.com/content/13/S1/P112
Page 2 of 2


Crossref

file:///data/core-remote/dit/data/Springer-OA/pdf/c22/aHR0cDovL2xpbmsuc3ByaW5nZXIuY29tLzEwLjExODYvMTU0Ni0wMDk2LTEzLVMxLVAxMTIucGRm.pdf

Validity and reliability of medication adherence scale in FMF

Abstract

Similar works

Full text

Available Versions

Springer - Publisher Connector

Springer - Publisher Connector

Crossref